Which of the following nucleoside and nucleotide analogues can be used as an antibiotic?
Which nitrogenous base is not present in DNA?
Deoxyribonucleic acid (DNA) is formed from:
Which enzyme is deficient in Lesch-Nyhan syndrome?
What is the first pyrimidine nucleotide to be synthesized?
Which of the following statements about DNA structure is true?
Apart from occurring in nucleic acids, pyrimidines are also found in which of the following?
A 4-year-old male with mental retardation, self-mutilation, and hyperuricemia is likely to have a deficiency of an enzyme involved in which of the following metabolic pathways?
What is present on the 3' end of all functional, mature tRNAs?
Which amino acid does NOT contribute to the biosynthesis of purine ribonucleotides?
Explanation: **Explanation:** The correct answer is **Fluorocytosine (5-Fluorocytosine or 5-FC)**. **Why it is correct:** Fluorocytosine is a pyrimidine analogue used specifically as an **antifungal antibiotic**. Its selectivity stems from the fact that fungal cells possess the enzyme **cytosine deaminase**, which converts 5-FC into 5-fluorouracil (5-FU). 5-FU is then metabolized into 5-FdUMP, a potent inhibitor of **thymidylate synthase**, thereby halting DNA synthesis in the fungus. Human cells lack cytosine deaminase, making the drug relatively non-toxic to the host. **Why the other options are incorrect:** * **Fluorodeoxyuridine (5-FdU):** This is a pyrimidine analogue used primarily as a **chemotherapeutic agent** (anticancer) rather than an antibiotic. * **Aminopterin & Methotrexate:** These are **folate analogues** (antifolates) that inhibit the enzyme **dihydrofolate reductase (DHFR)**. While they interfere with nucleotide synthesis, they are used as immunosuppressants or anticancer drugs, not as antibiotics. **High-Yield Clinical Pearls for NEET-PG:** * **Synergy:** 5-FC is frequently used in combination with **Amphotericin B** for treating Cryptococcal meningitis to enhance penetration and prevent resistance. * **Side Effects:** Despite its selectivity, 5-FC can cause dose-dependent **bone marrow suppression** due to the conversion of some 5-FC to 5-FU by human intestinal microflora. * **Mechanism Landmark:** Remember that 5-FC acts by inhibiting **Thymidylate Synthase** (via its metabolite 5-FdUMP), a common target for several pyrimidine-based drugs.
Explanation: **Explanation:** The fundamental difference between DNA (Deoxyribonucleic acid) and RNA (Ribonucleic acid) lies in their pentose sugar and their nitrogenous base composition. Both nucleic acids utilize four nitrogenous bases, but they differ in one specific pyrimidine. **Why Uracil is the Correct Answer:** Uracil is a pyrimidine base found exclusively in **RNA**. In DNA, the pyrimidine **Thymine** (5-methyluracil) is used instead. The presence of thymine in DNA is a crucial evolutionary adaptation for genetic stability; if DNA used uracil, the cell would have difficulty distinguishing between naturally occurring uracil and uracil formed by the spontaneous deamination of cytosine, leading to frequent mutations. **Analysis of Incorrect Options:** * **Adenine (A) & Guanine (G):** These are **Purines** (double-ring structures) and are present in both DNA and RNA. * **Thymine (T):** This is a **Pyrimidine** specific to DNA. It pairs with Adenine via two hydrogen bonds. **High-Yield NEET-PG Clinical Pearls:** 1. **Thymine vs. Uracil:** Thymine is chemically known as **5-methyluracil**. The methylation of uracil to thymine is catalyzed by the enzyme *thymidylate synthase*, a key target for the chemotherapy drug **5-Fluorouracil (5-FU)**. 2. **Base Pairing:** In DNA, A pairs with T (2 hydrogen bonds) and G pairs with C (3 hydrogen bonds). Higher G-C content increases the melting temperature ($T_m$) of DNA. 3. **Deamination:** Spontaneous deamination of **Cytosine** produces **Uracil**. This is a common type of DNA damage repaired by the *Base Excision Repair (BER)* pathway using the enzyme *Uracil DNA Glycosylase*.
Explanation: ### Explanation The synthesis of DNA requires deoxyribonucleotides (dNTPs). The critical step in converting RNA components into DNA components is the reduction of the sugar moiety, which occurs at a specific stage of phosphorylation. **Why Ribonucleotide Diphosphate is Correct:** The enzyme **Ribonucleotide Reductase (RNR)** is responsible for converting ribonucleotides into deoxyribonucleotides. This enzyme specifically acts on **ribonucleotide diphosphates (rNDPs)** (e.g., ADP, GDP, CDP, UDP) to convert them into **deoxyribonucleotide diphosphates (dNDPs)** (e.g., dADP, dGDP, dCDP, dUDP). These dNDPs are subsequently phosphorylated by kinases into dNTPs, which serve as the actual building blocks for DNA polymerase during replication. **Analysis of Incorrect Options:** * **A. Ribonuclease:** This is an enzyme that degrades RNA into smaller components; it is not a substrate for DNA synthesis. * **B. Ribonucleotide monophosphate (rNMP):** RNR does not recognize monophosphates as substrates. * **D. Ribonucleotide triphosphate (rNTP):** While dNTPs are the final precursors added to the DNA chain, the *formation* of the "deoxy" version happens at the diphosphate level. (Note: In some prokaryotes, RNR can act on triphosphates, but in humans/eukaryotes, it is strictly diphosphates). **NEET-PG High-Yield Pearls:** * **Ribonucleotide Reductase (RNR):** This is the **rate-limiting enzyme** for DNA synthesis. It requires **Thioredoxin** (and NADPH) as a cofactor to provide reducing equivalents. * **Clinical Correlation:** The drug **Hydroxyurea** inhibits Ribonucleotide Reductase. It is used clinically in Sickle Cell Anemia (to increase HbF) and in Myeloproliferative disorders (to inhibit rapid DNA synthesis). * **Regulation:** RNR is inhibited by dATP (feedback inhibition) and activated by ATP.
Explanation: **Explanation:** **Lesch-Nyhan Syndrome (LNS)** is an X-linked recessive disorder characterized by a deficiency of the enzyme **Hypoxanthine-Guanine Phosphoribosyltransferase (HGPRT)**. **Why HGPRT is the correct answer:** HGPRT is a key enzyme in the **Purine Salvage Pathway**. It converts hypoxanthine to IMP and guanine to GMP. When HGPRT is deficient, these purine bases cannot be salvaged and are instead degraded into **uric acid**, leading to severe hyperuricemia. Furthermore, the failure of the salvage pathway results in a compensatory increase in *de novo* purine synthesis (due to increased PRPP levels), further exacerbating uric acid production. **Why other options are incorrect:** * **GTRT:** This is not a recognized enzyme in purine metabolism. It may be a distractor for "Glutamine-PRPP Amidotransferase," which is the rate-limiting enzyme of *de novo* purine synthesis. * **Glutaminase:** This enzyme converts glutamine to glutamate. While glutamine is a nitrogen donor in purine synthesis, its deficiency does not cause Lesch-Nyhan syndrome. * **Transcarboxylase:** These enzymes are involved in fatty acid synthesis and gluconeogenesis (e.g., Pyruvate carboxylase), not purine metabolism. **High-Yield Clinical Pearls for NEET-PG:** * **Clinical Triad:** Hyperuricemia (orange sand in diapers/stones), Neurological disability (spasticity/choreoathetosis), and **Self-mutilation** (biting lips/fingers). * **Biochemical Hallmark:** Elevated PRPP levels and low IMP/GMP levels. * **Diagnosis:** High serum uric acid and urinary uric acid-to-creatinine ratio. * **Treatment:** Allopurinol or Febuxostat (manages hyperuricemia but does not reverse neurological symptoms).
Explanation: **Explanation:** In pyrimidine synthesis, the nitrogenous base ring is synthesized first and then attached to the ribose-5-phosphate sugar. This is a key distinction from purine synthesis, where the ring is built directly onto the sugar. **1. Why Orotidine monophosphate (OMP) is correct:** The synthesis begins with the formation of Carbamoyl Phosphate, which eventually forms **Orotic acid**. The enzyme **ORPT** (Orotate phosphoribosyltransferase) then transfers a ribose-5-phosphate group from PRPP to Orotic acid. This reaction produces **Orotidine monophosphate (OMP)**, which is the very first nucleotide (base + sugar + phosphate) formed in the de novo pyrimidine pathway. OMP is subsequently decarboxylated by OMP decarboxylase to form UMP. **2. Why the other options are incorrect:** * **Uridine monophosphate (UMP):** While UMP is the "parent" pyrimidine from which others are derived, it is formed *after* the decarboxylation of OMP. * **Thymidine monophosphate (TMP):** This is a downstream product formed from dUDP/dUMP via the action of Thymidylate synthase. * **Inosine monophosphate (IMP):** This is the first nucleotide formed in the **Purine** synthesis pathway, not the pyrimidine pathway. **High-Yield Clinical Pearls for NEET-PG:** * **Bifunctional Enzyme:** In humans, ORPT and OMP decarboxylase are two domains of a single polypeptide chain called **UMP Synthase**. * **Orotic Aciduria:** A deficiency in UMP Synthase leads to Orotic Aciduria (Type I), characterized by megaloblastic anemia (unresponsive to B12/Folate) and growth retardation. It is treated with **oral Uridine** to bypass the metabolic block. * **Rate-limiting step:** The formation of Carbamoyl Phosphate by **CPS-II** (cytosolic) is the regulated step of pyrimidine synthesis.
Explanation: **Explanation:** **1. Why Option A is Correct:** In a DNA polynucleotide chain, every single nucleotide is linked to the next via a **3'–5' phosphodiester bond**. This bond connects the 3' carbon of one deoxyribose sugar to the 5' phosphate group of the adjacent nucleotide. This continuous linkage forms the sugar-phosphate backbone, ensuring structural integrity. No nucleotide exists in isolation within the polymer; even the terminal nucleotides have one end involved in a linkage. **2. Analysis of Incorrect Options:** * **Options B & C:** While it is a fundamental fact that DNA strands are **antiparallel** (one runs 5'→3' and the other 3'→5'), in the context of specific biochemical definitions regarding the "linkage" of the entire polymer structure, Option A is often prioritized in certain standardized formats to emphasize the continuity of the backbone. *Note: In most standard biological contexts, B is also a true statement; however, the question asks for the most definitive structural truth regarding nucleotide involvement.* * **Option D:** In the B-DNA model (the most common form), the nitrogenous bases are not perpendicular to the helix axis; they are **stacked** relatively perpendicular to the axis but exhibit a slight "propeller twist" and "tilt." **3. NEET-PG High-Yield Clinical Pearls:** * **Phosphodiester Bonds:** These are covalent bonds. They are the targets of **nucleases** (DNase/RNase). * **Chargaff’s Rule:** In double-stranded DNA, A=T and G=C; therefore, Purines = Pyrimidines. * **Z-DNA:** Unlike the standard right-handed B-DNA, Z-DNA is a **left-handed** helix with a zigzag backbone, often found in regions with alternating purine-pyrimidine sequences. * **Denaturation:** The G-C bond is stronger (3 hydrogen bonds) than the A-T bond (2 hydrogen bonds). DNA with high G-C content has a higher melting temperature ($T_m$).
Explanation: ### Explanation **Correct Answer: D. Thiamine** **1. Why Thiamine is Correct:** Thiamine (Vitamin B1) is a substituted pyrimidine derivative. Its chemical structure consists of a **pyrimidine ring** (specifically 2,5-dimethyl-6-aminopyrimidine) linked to a **thiazole ring** by a methylene bridge. While pyrimidines (Cytosine, Uracil, Thymine) are fundamental components of nucleotides and nucleic acids, thiamine represents a critical non-nucleic acid biological molecule where the pyrimidine nucleus is essential for its coenzyme function (Thiamine Pyrophosphate - TPP). **2. Why Other Options are Incorrect:** * **A & B (Theophylline and Theobromine):** These are **methylxanthines**. Xanthines are derivatives of **purines**, not pyrimidines. Theophylline (found in tea) and Theobromine (found in cocoa) share the fused imidazole-pyrimidine ring system characteristic of purines. * **C (Flavin mononucleotide - FMN):** FMN (derived from Vitamin B2/Riboflavin) contains an **isoalloxazine ring** system. While it functions as a prosthetic group in redox reactions, it does not contain a simple pyrimidine ring. **3. Clinical Pearls & High-Yield Facts for NEET-PG:** * **Thiamine Deficiency:** Leads to **Beriberi** (Dry: peripheral neuropathy; Wet: high-output heart failure) and **Wernicke-Korsakoff Syndrome** (triad of ophthalmoplegia, ataxia, and confusion), commonly seen in chronic alcoholics. * **Key Enzyme Cofactor:** TPP is a vital cofactor for: 1. Pyruvate Dehydrogenase (Link reaction) 2. $\alpha$-Ketoglutarate Dehydrogenase (TCA cycle) 3. Branched-chain $\alpha$-ketoacid dehydrogenase (MSUD) 4. Transketolase (HMP Shunt - used for clinical diagnosis of B1 deficiency). * **Other Pyrimidine Derivatives:** Apart from nucleic acids and B1, pyrimidines are found in barbiturates and certain sulfonamides.
Explanation: ### Explanation The clinical triad of **mental retardation (intellectual disability)**, **self-mutilation** (e.g., biting lips and fingers), and **hyperuricemia** (leading to gouty arthritis or orange sand-like crystals in diapers) is pathognomonic for **Lesch-Nyhan Syndrome**. **1. Why the Correct Answer is Right:** Lesch-Nyhan Syndrome is an X-linked recessive disorder caused by a complete deficiency of **Hypoxanthine-Guanine Phosphoribosyltransferase (HGPRT)**. This enzyme is crucial for the **Purine Salvage Pathway**, where it recycles hypoxanthine and guanine back into IMP and GMP, respectively. In its absence, these purines cannot be recycled and are instead shunted into the degradation pathway, leading to excessive production of **uric acid**. Additionally, the lack of salvage leads to increased *de novo* purine synthesis (due to high PRPP levels), further exacerbating hyperuricemia. **2. Analysis of Incorrect Options:** * **Option A:** Refers to **Alkaptonuria** (deficiency of homogentisate oxidase). It presents with dark urine, ochronosis, and arthritis, but not self-mutilation or hyperuricemia. * **Option B:** Refers to **Krabbe disease**. It is a lysosomal storage disorder presenting with demyelination, irritability, and developmental delay, but lacks the metabolic profile of gout. * **Option C:** Refers to **Maple Syrup Urine Disease (MSUD)**. It presents with a burnt-sugar urine odor, poor feeding, and neurological decline in neonates, not chronic self-mutilation. **3. NEET-PG High-Yield Pearls:** * **Mnemonic for HGPRT deficiency:** **H**yperuricemia, **G**out, **P**issed off (self-mutilation), **R**etardation, **D**ys**T**onia. * **Inheritance:** X-linked recessive (almost exclusively in males). * **Biochemical Hallmark:** Elevated serum uric acid and increased **PRPP (Phosphoribosyl pyrophosphate)** levels. * **Treatment:** Allopurinol or Febuxostat (manages uric acid but does not fix neurological symptoms).
Explanation: **Explanation:** **1. Why Option C is correct:** All functional, mature transfer RNA (tRNA) molecules possess a specific trinucleotide sequence at their 3' terminus: **5'-CCA-3'**. This sequence is added post-transcriptionally by the enzyme **tRNA nucleotidyltransferase**. The 3' hydroxyl group of the terminal **Adenosine (A)** serves as the attachment site for a specific amino acid, forming an aminoacyl-tRNA. This process, catalyzed by aminoacyl-tRNA synthetase, is essential for translating the genetic code into a polypeptide chain. **2. Why other options are incorrect:** * **Option A (Cloverleaf loop):** This refers to the secondary structure of tRNA, which includes the D-loop, T$\psi$C loop, and anticodon loop. It is the overall shape, not a specific sequence at the 3' end. * **Option B (Anticodon):** The anticodon is located in the **anticodon loop**, situated at the opposite end of the tRNA molecule from the 3' acceptor stem. It base-pairs with the mRNA codon. * **Option D (Codon):** A codon is a three-nucleotide sequence found on **mRNA**, not tRNA. **3. Clinical Pearls & High-Yield Facts for NEET-PG:** * **Acceptor Stem:** The 3' end is part of the "Acceptor Stem." Remember the mnemonic: **"CCA: Can Carry Amino acids."** * **Post-transcriptional Modification:** In eukaryotes, the CCA tail is not coded by the DNA but is added after transcription. * **Charging:** The process of attaching an amino acid to the 3' CCA end is called "charging" or "loading" of tRNA. * **T$\psi$C Loop:** Contains pseudouridine and ribothymidine; it is responsible for binding the tRNA to the **ribosomal surface** (70S or 80S). * **D-Loop:** Contains Dihydrouridine; it is involved in recognition by the specific **Aminoacyl-tRNA synthetase**.
Explanation: To master purine biosynthesis for NEET-PG, it is essential to memorize the specific contributors to the purine ring (Inosine Monophosphate - IMP). ### **Explanation** The purine ring is a bicyclic structure synthesized "de novo" by adding atoms to a ribose-5-phosphate base. The atoms are derived from specific amino acids, CO₂, and folate derivatives. * **Why Histidine is the Correct Answer:** While Histidine is a basic amino acid, it **does not** contribute any atoms to the purine ring. Interestingly, the relationship is actually the reverse: **ATP (a purine) is a precursor for the biosynthesis of Histidine** in plants and microorganisms. In humans, Histidine is an essential amino acid and must be obtained through diet. * **Why the Other Options are Incorrect:** * **Glycine (Option D):** This is the most significant contributor. It provides the entire C4, C5, and N7 backbone of the purine ring. * **Aspartate (Option A):** It provides the **Nitrogen at position 1 (N1)**. It also plays a role in the conversion of IMP to AMP. * **Glutamine/Glutamate (Option C):** Glutamine acts as the nitrogen donor for **N3 and N9** positions. (Note: While the question lists Glutamate, in biochemical pathways, Glutamine is the direct donor, often interconverted with glutamate). ### **High-Yield Clinical Pearls for NEET-PG** 1. **Mnemonic for Purine Sources:** **"CO2, Gly, Asp, Gln, and Formyl-THF."** * **Glycine:** Entire C4-C5-N7. * **Aspartate:** N1. * **Glutamine:** N3, N9. * **THFs (N10-formyl THF):** C2 and C8. * **CO₂:** C6. 2. **Rate-limiting step:** The conversion of PRPP to 5-phosphoribosylamine by **PRPP glutamyl amidotransferase**. 3. **Drug Link:** **Methotrexate** inhibits dihydrofolate reductase, depleting the folate pool and thus inhibiting C2 and C8 synthesis in purines.
Nucleotide Structure and Function
Practice Questions
DNA Structure and Replication
Practice Questions
RNA Structure and Types
Practice Questions
Transcription: RNA Synthesis
Practice Questions
Post-Transcriptional Modifications
Practice Questions
Translation: Protein Synthesis
Practice Questions
Genetic Code and Codon Usage
Practice Questions
Regulation of Gene Expression
Practice Questions
Mutations and DNA Repair
Practice Questions
Purine Metabolism and Disorders
Practice Questions
Pyrimidine Metabolism and Disorders
Practice Questions
Nucleotide Degradation and Salvage Pathways
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free